CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.

@article{Meur2006CYP3A53IS,
  title={CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.},
  author={Yannick Le Meur and Nassim Djebli and Jean-Christophe Szelag and Guillaume Hoizey and Olivier Toupance and Jean Philippe R{\'e}rolle and Pierre Marquet},
  journal={Clinical pharmacology and therapeutics},
  year={2006},
  volume={80 1},
  pages={51-60}
}
BACKGROUND The low and highly variable oral bioavailability of the immunosuppressant sirolimus is thought to result partly from genetic polymorphism of the CYP3A5 gene. METHODS This study aimed to evaluate the contribution of the CYP3A5 single-nucleotide polymorphism A6986G to the interindividual variability of sirolimus pharmacokinetics in 47 renal transplant patients at steady state, 21 of whom were also followed up for the first 3 months after transplantation. The patients were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…